Vanrx Pharmasystems Is #1 on the Deloitte Technology Fast 50 List of the Fastest Growing Technology Companies in Canada

Thursday, November 15, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Next-generation medicines manufactured using Vancouver company's technology

VANCOUVER, Canada, Nov. 15, 2018 /PRNewswire-PRWeb/ -- Deloitte, an international financial advisory firm, has named

Vanrx Pharmasystems as the fastest growing technology company in Canada on its 2018 Technology Fast 50™ list.

The Fast 50 list celebrates innovation in the form of rapid revenue growth from companies in the fields of hardware, software, telecommunications, emerging technology, and digital media. Companies are ranked by their revenue-growth percentage over the past four years of operations.

Vanrx's revenue growth percentage was 19,342%, placing it first on the overall list.

"Vanrx would like to thank its employees, customers, investors, suppliers and partner companies for supporting the company's rapid growth over the past four years," said Chris Procyshyn, chief executive officer and co-founder of Vanrx Pharmasystems.

"Our mission is to make it possible for more companies to operate world-class aseptic filling operations. If sterile injectables manufacturing becomes more flexible and cost-effective, life-changing therapies can be made more widely available," he adds.

"Business is changing rapidly, and what used to work a few years ago isn't a recipe for what will work in the future," said Erica Pretorius, Partner and National Leader for the Technology Fast 50™ program at Deloitte Canada. "Fast 50 winners are a beacon of innovation and I'm looking forward to how they will change the business and technology landscape in the future."

Vanrx manufactures machines to fill liquid pharmaceuticals into vials, syringes or cartridges. These machines combine robotics, machine vision and gloveless isolator technologies. Vanrx's Aseptic Filling Workcells help pharmaceutical companies manufacture complex therapies with higher levels of flexibility and sterility assurance. Customers can build filling capacity faster, to maximize revenue in the patent window and reduce manufacturing costs.

To develop and manufacture its robotic aseptic filling machines, Vanrx's engineering focus is on mechatronics, controls and automation.

To qualify for the Deloitte Technology Fast 50 ranking, companies must have been in business for at least four years, have revenues of at least $5 million, be headquartered in Canada, own proprietary technology, conduct research and development activities in Canada and invest a minimum of five percent of gross revenues in R&D.

About the Deloitte Technology Fast 50™

The Deloitte Technology Fast 50 program is Canada's pre-eminent technology awards program. Celebrating business growth, innovation and entrepreneurship, the program features three distinct categories including the Technology Fast 50 Ranking, Companies-to-Watch Awards (early-stage Canadian tech companies with the potential to be a future Deloitte Technology Fast 50 candidate) and the Leadership Awards (companies that demonstrate technological leadership and innovation within the industry). Program sponsors include Deloitte, 3C Innovation, BCF Business Law, Bank of Montreal, Bennett Jones, CBRE, First West Capital and OMERS Ventures. For further information, visit [ __title__ .

About Vanrx Pharmasystems

Vanrx Pharmasystems makes the most technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes, or cartridges. The company was founded by pharmaceutical industry veterans to create the systems needed to make the next generation of innovative therapies. For more information, please visit

For more information, or to schedule interviews with CEO Chris Procyshyn, please contact:

Eric Petz Senior Marketing Manager Vanrx Pharmasystems Phone: +1.778.228.4177 Email:


SOURCE Vanrx Pharmasystems

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store